According to the company, its new protein-based vaccine is unique because it targets sequences of SARS-CoV-2 and its variants, as well as sequences common to other coronaviruses. Its aim is to induce broad and long-lasting immune responses.
PanCov falls within the World Health Organisation’s (WHO) booster vaccination strategy for the world's health systems.
The objective of this health policy is to avoid a resurgence of the pandemic and its medico-economic consequences on world population.
This strategy led to the creation by the US of the NextGen programme defining the requirements of next generation COVID-19 vaccines.
These vaccines must be multi-variant, long-lasting, and both easy and cheaper to manufacture and store. LinKivVax claims PanCov meets all these criteria.
André-Jacques Auberton-Hervé, president and co-founder of LinKinVax, said: “Our ambition is to develop a robust and long-lasting vaccine with a booster effect, effective on the multiple variants of SARS-CoV-2, as well as on other coronaviruses to prevent the emergence of new pandemics.”
“The data collected during the production process with GTP Bioways will help us accelerate the production of new vaccines generated by our innovative platform. The use and training of the latest artificial intelligence (AI) tools on these databases, which we will continue to enrich, form an integral part of LinKinVax's differentiation strategy to accelerate the production of effective vaccine solutions in the event of a pandemic.”
Alain Sainsot, president of GTP Bioways, added: “Our teams in Toulouse and Saint-Julien-en-Genevoix are delighted to have concluded in a timely and efficient manner the collaboration with LinKinVax announced in March 2022, that led to the production of the first GMP batch of this next generation COVID-19 vaccine.”
“This partnership highlights the ability of the French industry to provide solutions to unmet global health needs. André-Jacques Auberton-Hervé, CEO of LinKinVax, has also personally helped our digital strategy by putting us in touch with global AI leaders, to boost our biomanufacturing offer and position GTP Bioways at the cutting edge of innovation.”
The release of the PanCov GMP batch with compliance validation and toxicology results is expected in Q3 2023 and the clinical trials are due to start early 2024.
